Company ProfilePremium

Bolak Company Limited

Company Profile Analysis

Ticker: 002760.KS주식회사 보락

ESOMAR 23 Corporate BadgeISO Certifications Badge
Bolak Company Limited - Company showcase

Year Founded & Workforce

1959

141 Employees

Bolak Company Limited logo

Bolak Company Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Bolak Company Limited Overview

Bolak is one of Korea's longest-established specialty ingredient manufacturers. It has been listed on the KOSPI for decades and operates from a single integrated site in Hwaseong, Gyeonggi Province. The company supplies flavours, food colours, chewing-gum base, and functional food additives to Korean confectionery, beverage, dairy, and consumer-goods producers. It also manufactures pharmaceutical raw materials, notably herbal-extract APIs, natural paclitaxel, docetaxel trihydrate, and cellulose-based excipients (Na-CMC and Ca-CMC), along with cosmetic ingredients and fragrances. With FY2025 revenue of KRW 50.1bn and about 140 staff, Bolak is a micro-cap and a price-taker relative to global flavour houses. Its edge is breadth of portfolio, long-standing domestic customer relationships, a debt-light balance sheet (net cash of KRW 6.8bn at FY2025), and a regulated API capability that most domestic food-additive peers lack. Margins are thin and volatile (operating margin between −3.8% and 6.8% over FY2021–FY2025). The equity is heavily influenced by the controlling family's widely reported connection to the LG Group chairman's household. [S1, S2, S3, S10, S11]


What the company does

Bolak develops, manufactures, and sells ingredients for four broad customer universes:

  1. Food and beverage manufacturers. Products include flavours for confectionery, beverages, dairy, seasonings, and "micron" flavour formats; food colours (natural extracts, synthetic, and blended synthetic); chewing-gum base; and a wide range of additives including sweeteners, surfactants, preservatives, antioxidants, thickeners, caffeine, and baking powder. [S2, S8, S16]

  2. Pharmaceutical manufacturers. Products include herbal-extract APIs (dry and soft extract powders, fluid extracts, tinctures), the oncology APIs natural paclitaxel and docetaxel trihydrate, and the cellulose derivatives Na-CMC and Ca-CMC used as excipients. [S2, S16]

  3. Health functional food producers. Products include green tea extracts, soy isoflavones, and ginseng extracts. [S2, S7]

  4. Cosmetics, personal care, and household-goods makers. Products include cosmetic ingredients and fragrances for perfumes, cosmetics, hair products, daily-use goods, toilet soaps, candles, and industrial products, plus whitening agents and abrasives. Legacy profiles also cite flavours for toothpaste and tobacco, and production of chocolate and Ca-CMC. [S2, S18, S21]

The company's own description

Bolak's English-language annual report is not published, and the DART business report narrative could not be accessed directly. Data providers that summarise the DART filing consistently describe the company as manufacturing and selling food ingredients, pharmaceutical raw materials, functional materials, and cosmetic ingredients in Korea and internationally. [S2, S7] Morningstar characterises it more narrowly as a manufacturer of food additives and active pharmaceutical ingredients. [S6] The verbatim "business overview" chapter of the FY2025 business report is not publicly disclosed in accessible sources.

Business and revenue model

DimensionCharacterisation
Revenue modelAlmost entirely product sales (B2B ingredient manufacturing). No subscription, licensing, or service revenue is disclosed. A small fee-income line of about KRW 0.17–0.22bn per year appears in non-operating income [S5].
Value-chain positionMid-stream. Bolak converts commodity and botanical inputs (raw materials were KRW 27.8bn, about 66% of FY2025 cost of sales [S5]) into formulated ingredients sold to branded consumer-goods and pharmaceutical companies. It does not sell to consumers [S3].
Customer typesKorean confectionery, beverage, dairy, and bakery producers; gum manufacturers; generic and herbal pharmaceutical companies; health functional food producers; cosmetics and household-goods companies. Named customers are not publicly disclosed, apart from media allegations of material sales to LG Household & Health Care (see Section 19) [S10].
End marketsPackaged food and confectionery, beverages, dairy, pharmaceuticals (herbal medicines, oncology generics, excipients), nutraceuticals, cosmetics and personal care.
Mix (Q2 FY2026)Food additives 56%, other 24%, APIs 20% of quarterly revenue [S4].
GeographyOverwhelmingly domestic. Aggregator data imply LTM export revenue of only KRW 0.8–2.3bn (about 2–5% of sales) over Jun 2025 – Jun 2026 [S5]. See Section 7 for caveats.

Independent characterisation

Bolak is best understood as a diversified domestic ingredient workshop with an embedded API niche. It is not a scaled flavour house. Annual revenue of about KRW 50bn is roughly one-hundredth of Symrise's or Givaudan's flavour-and-fragrance sales [S19, S20]. Gross margins of 9–17% over FY2021–FY2025 [S2] are characteristic of commodity-blending and contract manufacturing, not proprietary formulation. Global leaders, by contrast, run gross margins above 40% (Givaudan reported 43.5% for 2025 [S19]).

Three features distinguish Bolak from a pure commodity blender:

Regulated pharmaceutical manufacturing: It produces natural paclitaxel and docetaxel trihydrate. This places it in a niche oncology API market that one industry study sizes at roughly USD 200M globally by 2030 [S14].

Gum base capability: Gum base is a technically specific, consolidated product category with few domestic producers [S8].

Large, conservatively financed asset base: Total assets are KRW 59.2bn, including land carried at KRW 19.1bn [S2]. Book value per share is KRW 814 [S2], close to the share price.

Strategy

Stated strategy. Bolak publishes no investor-day materials, mid-term plan, or English-language strategy statement. The strategy and outlook narrative in the FY2025 DART business report was not accessible, so verbatim strategic themes are not publicly disclosed in accessible sources.

Initiatives observable from filings and financials (last 24 months):

Not publicly disclosed: sustainability or ESG commitments, cost programmes with quantified targets, new business launches, partnerships, and medium-term financial targets or guidance.

Products & Services

Product-level specifications, launch years, pricing models, and named flagship brands are not publicly disclosed in accessible sources. The company sells under its corporate name to B2B customers, and the website catalogue could not be retrieved. The catalogue below is the most granular publicly documented list, organised by revenue bucket.

Food additives (56% of Q2 FY2026 revenue)

Product lineDescription and known capabilitiesTarget customerSource
Confectionery flavoursFlavours for candy, gum, chocolate, ice cream, and frozen confectionsConfectionery and ice-cream makersS2, S21
Beverage flavoursFlavours for soft drinks and other beveragesBeverage bottlers and brand ownersS2, S21
Dairy flavoursFlavours for dairy productsDairy processorsS2, S8
"Micron" flavoursListed as a distinct flavour format; likely a fine-particle or encapsulated powder flavour (characterisation not company-confirmed)Dry-mix, powder, and confectionery applicationsS2
Seasoning flavours and herbal essencesSavoury seasoning flavours; herbal essencesProcessed-food and seasoning makersS8
Oral-care and tobacco flavoursFlavours used in toothpaste and tobaccoOral-care and tobacco manufacturersS18, S21
Food colours, naturalNaturally extracted colouring agentsFood and beverage makersS2, S8
Food colours, synthetic and blendedSynthetic and mixed synthetic colouring agentsFood, confectionery, and pharma coating usersS8
Chewing-gum baseGum base for stick, tablet, coated, powder-pressed, centre-filled, and sugar-free gumGum manufacturersS8
SweetenersSweetening agentsFood and beverage makersS2
Preservatives and antioxidantsShelf-life and oxidation-control additivesFood processorsS2, S3
Thickeners and thickening agentsTexture and viscosity modifiers (including CMC grades)Food processorsS2
Surfactants and emulsifiersSurface-active agentsFood and cosmetics processorsS2
CaffeineCaffeine ingredientBeverage and pharma customersS2
Baking powderLeavening agentBakery and industrial food producersS2
ChocolateListed in legacy profiles as a productConfectionery customersS18, S21

Active pharmaceutical ingredients (20% of Q2 FY2026 revenue)

Product lineDescription and known capabilitiesTarget customerSource
Dry extract powdersStandardised herbal extract APIs in powder formHerbal and ethical pharmaceutical companiesS2, S8
Soft (viscous) extractsConcentrated viscous herbal extractsHerbal medicine manufacturersS2, S8
Fluid extractsLiquid botanical extractsPharmaceutical manufacturersS2, S8
TincturesAlcoholic botanical extractsPharmaceutical manufacturersS2, S8
Natural paclitaxelTaxane cytotoxic oncology API derived from yew biomass (natural route)Oncology generic and injectable formulatorsS2, S16
Docetaxel trihydrateSemi-synthetic taxane oncology APIOncology generic formulatorsS2, S16
Na-CMC (sodium carboxymethylcellulose)Cellulose ether excipient (binder, thickener)Pharma and foodS2, S16
Ca-CMC (calcium carboxymethylcellulose)Cellulose ether excipient (disintegrant)Pharma tablet manufacturersS2, S18

Paclitaxel IP. In October 2024, media reported that Bolak holds a patent on a drug-delivery system for paclitaxel relevant to Daehwa Pharmaceutical's oral formulation Liporaxel. Daehwa developed Liporaxel on its DHLASED lipid-based self-emulsifying delivery platform. [S12] The commercial terms (licence, royalty, supply) linking Bolak to Liporaxel are not publicly disclosed. A securities-industry source quoted at the time flagged uncertainty over any earnings contribution. [S12]

Health functional food materials (reported within "Other" or food; classification not confirmed)

Product lineDescriptionTarget customerSource
Green tea extractsBotanical extract for functional foodsHealth functional food brandsS2
Soy isoflavonesPhyto-oestrogen extractNutraceutical brandsS2
Ginseng extractsKorean ginseng extract materialsHealth functional food and herbal brandsS2

Cosmetic ingredients and fragrances (within "Other")

Product lineDescriptionTarget customerSource
Fine and functional fragrancesFragrances for perfumes, cosmetics, hair products, daily-use goods, toilet soaps, candles, and industrial productsCosmetics, personal-care, and household-goods makersS2
Cosmetic ingredientsIncluding whitening agents and abrasivesCosmetics manufacturersS2
Industrial odorants and medical fragrancesOdorants for industrial use; fragrances for medical productsIndustrial and medical-device customersS8

Financial Narrative

All figures are from separate financial statements under K-IFRS. Primary dataset: S&P Global Market Intelligence via StockAnalysis.com [S2], cross-checked against DART-based ETF쇼핑 data [S3]. The two agree to within rounding on revenue, operating income, and net income. Gross-profit and R&D classifications differ slightly between providers: S&P shows FY2025 gross profit of KRW 7.83bn versus KRW 7.9bn on ETF쇼핑.

Income statement: notes and sources

Source: S2 (FY2021–FY2025). ValueLine's DART-based EBITDA for FY2025 is KRW 4.11bn [S5], versus KRW 3.93bn on S&P's definition.

Per-share data (KRW)

Source: S2 (EPS, BVPS, FCF/share); S3 (DPS, by fiscal year of record date). No dilutive instruments are reported.

Margins and growth (%)

Source: S2; R&D intensity computed. Revenue CAGR FY2021–FY2025 = 5.96% (computed from S2). Revenue CAGR FY2016–FY2025 = 3.84% (computed from S3).

Ten-year context: notes and sources

Source: S3 (DART business reports, FY2016–FY2025): ### Balance sheet: notes and sources

Source: S2. Short- and long-term debt splits computed from S2 line items. Goodwill is nil; intangibles are "other intangible assets" only. Land is carried at KRW 19.08bn in every year from FY2021 to FY2025 [S2].

Cash flow: notes and sources

Source: S2. Buybacks are nil in FY2021–FY2025. A KRW 1.5bn trust was contracted in Jul 2026 [S3].

Ratios

Source: computed from S2 data. ROIC uses a notional 20% tax rate because Bolak's effective tax rate swings widely (5.1% in FY2025; negative in FY2023–FY2024). S&P's own TTM figures to Jun 2026 are ROE 5.19% and ROIC 4.46% [S2].

Net debt / EBITDA. FY2021: 0.38x. FY2022: 0.01x. FY2023 and FY2025: net cash (−0.48x and −1.74x). FY2024: not meaningful, because EBITDA was negative (−KRW 26M) while the company held net cash. [S2; computed]

Latest interim position (LTM to 30 June 2026)

Source: S2: Q2 FY2026 preliminary results (29 Jul 2026) were revenue KRW 12.5bn, operating profit KRW 0.7bn, and net income KRW 0.9bn [S3]. Investing.com reports Q1 FY2026 revenue of KRW 11.21bn and EPS of KRW 9.06 [S15]. H1 FY2026 revenue was therefore about KRW 23.7bn. The fall in LTM revenue from KRW 50.1bn to KRW 47.0bn implies H1 FY2026 revenue was roughly 11–12% below H1 FY2025 (computed). At 30 Jun 2026, cash was KRW 7.47bn, debt KRW 1.06bn, net cash KRW 6.41bn, and equity KRW 49.68bn (book value per share KRW 829.47) [S2].

Commentary on trends, inflections, and drivers

Revenue. Bolak's top line was essentially stagnant for most of the decade (KRW 33.5–38.3bn in FY2017–FY2020 [S3]). It then stepped up in FY2022, when revenue grew 21.8% to KRW 48.4bn [S2]. The step-up coincided with the 2022 global food-inflation cycle, and inventory build in FY2022 (KRW 3.3bn cash outflow) suggests price pass-through on higher input costs rather than purely volume-driven growth [S2]. Revenue then plateaued at KRW 47–50bn. FY2025 reached a 10-year high of KRW 50.1bn, but the LTM figure has since slipped to KRW 47.0bn. Export revenue in particular appears to have declined. The absence of a disclosed segment history prevents attribution between food additives and APIs.

Gross margin is the swing factor. Gross margin collapsed from 17.0% in FY2022 to 9.0% in FY2024, then recovered to 15.6% in FY2025 and 17.2% LTM [S2]. Two observations point to cost-side and inventory-valuation effects, not price competition alone:

  • ValueLine's cost breakdown shows raw-material cost broadly flat at KRW 27–30bn, while "other" cost-of-sales items swung sharply between periods [S5].

  • FY2024 carried an unusual KRW 0.98bn "other operating expense" [S2].

The nature of the FY2024 charge (possible inventory write-down or impairment) is not publicly disclosed in accessible sources. The record inventory of KRW 16.9bn at FY2024 year-end, followed by a KRW 4.0bn reduction in FY2025, is consistent with a destocking and write-down cycle [S2].

Operating leverage is high relative to scale. SG&A plus R&D runs at about KRW 5.3–5.6bn per year [S2]. Each percentage point of gross margin is worth about KRW 0.5bn, a quarter of FY2025 operating profit. Labour is a large fixed cost: payroll was KRW 8.43bn in FY2025, 16.8% of revenue [S1].

Cash generation inflected in FY2025. Operating cash flow reached KRW 7.17bn, about 3x net income, driven by the KRW 3.5bn inventory release [S2]. This funded KRW 1.09bn of debt repayment and lifted cash to KRW 7.9bn. The LTM figure to June 2026 (OCF KRW 4.6bn, FCF KRW 3.2bn) shows the working-capital tailwind fading [S2]. Underlying cash earnings (net income plus D&A) are about KRW 4bn per year.

Balance sheet. The balance sheet is very conservative. Equity of KRW 48.7bn funds 82% of assets. Debt fell to KRW 1.1bn at FY2025 [S2], of which KRW 1.03bn is current and due in 2026. The asset base is dominated by property, plant and equipment (KRW 26.4bn, including land at historical cost of KRW 19.1bn) and inventory [S2]. Return on capital is structurally low (ROE 4.8% in FY2025) because a large equity base supports a thin-margin business.

Capital intensity is low. Capex averaged KRW 0.68bn per year over FY2021–FY2025, against D&A of about KRW 1.9bn [S2]. The asset base is therefore being depreciated faster than it is renewed. FY2025 capex of KRW 1.26bn is the highest in the period.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment (Q2 FY2026) Overview

Segment (Q2 FY2026)Share of revenue (%)Implied revenue (KRW Mn)

Food additives

567,000

Other (incl. cosmetic ingredients, fragrances, functional materials, merchandise)

243,000

Active pharmaceutical ingredients

202,500

Total

10012,500

Income Statement

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Mn)

39,76448,43546,77447,60050,116

Cost of revenue (KRW Mn)

33,31540,20941,13543,30442,282

Gross profit (KRW Mn)

6,4498,2255,6394,2967,834

SG&A (KRW Mn)

3,4313,6563,7434,0574,551

R&D expense (KRW Mn)

1,1371,071990870796

Operating income (KRW Mn)

1,6923,283506-1,7922,230

D&A (KRW Mn)

2,0401,9821,8911,7661,704

EBITDA (KRW Mn)

3,7325,2652,396-263,934

Interest expense (KRW Mn)

7568909766

Pre-tax income (KRW Mn)

1,8413,389724-1,5532,465

Income tax (KRW Mn)

146320-134-44126

Net income (KRW Mn)

1,6953,069858-1,5102,340

Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

EPS basic (KRW)

28.3051.2414.32-25.2039.06

EPS diluted (KRW)

28.3051.2414.32-25.2039.06

Dividend per share (KRW)

57557

Book value per share (KRW)

760.33807.74814.34778.81813.53

Free cash flow per share (KRW)

9.1631.7015.9210.6298.60

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

3.8421.81-3.431.775.29

Gross margin (%)

16.2216.9812.059.0315.63

Operating margin (%)

4.256.781.08-3.764.45

EBITDA margin (%)

9.3910.875.12-0.067.85

Net margin (%)

4.266.341.83-3.174.67

R&D / revenue (%)

2.862.212.121.831.59

Income Statement and Margin Analysis (%)

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

35.733.533.836.138.339.848.446.847.650.1

Operating profit (KRW Bn)

2.01.31.30.60.11.73.30.5-1.82.2

Net income (KRW Bn)

3.01.21.10.60.41.73.10.9-1.52.3

Gross margin (%)

16.416.316.213.612.416.417.212.29.215.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Mn)

56,31860,91257,92859,28259,241

Cash and equivalents (KRW Mn)

1,9123,1623,2953,6277,940

Receivables (KRW Mn)

6,1747,8926,7686,3626,455

Inventory (KRW Mn)

11,23814,21014,67016,89612,865

Total current assets (KRW Mn)

20,69326,26425,12027,85427,966

Property, plant and equipment (KRW Mn)

30,59529,34328,02626,67726,373

Goodwill and intangibles (KRW Mn)

317257197137112

Short-term debt incl. current LTD and leases (KRW Mn)

843,07980361,095

Long-term debt incl. leases (KRW Mn)

3,2321532,0732,0419

Total debt (KRW Mn)

3,3153,2322,1532,0771,104

Net debt (KRW Mn; negative = net cash)

1,40370-1,143-1,550-6,835

Total current liabilities (KRW Mn)

4,8429,8104,6595,9317,973

Total liabilities (KRW Mn)

10,77412,5299,14912,63110,511

Shareholders' equity (KRW Mn)

45,54448,38448,77946,65148,731

Working capital (KRW Mn)

15,85116,45520,46221,92319,992

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Mn)

1,1782,5481,5239047,166

Capital expenditure (KRW Mn)

-629-650-569-268-1,260

Free cash flow (KRW Mn)

5491,8999546365,906

Change in inventory (KRW Mn)

-1,726-3,312-552-2,9063,534

Dividends paid (KRW Mn)

-240-300-419-300-300

Share buybacks (KRW Mn)

00000

Net debt issued / repaid (KRW Mn)

-132-84-1,079-89-1,094

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, year-end equity (%)

3.726.341.76-3.244.80

ROA, year-end assets (%)

3.015.041.48-2.553.95

ROIC, EBIT x (1-20%) / (equity + debt - cash) (%)

2.885.420.85-3.184.26

Current ratio (x)

4.272.685.394.703.51

Debt / equity (x)

0.0730.0670.0440.0450.023

Interest coverage, EBIT / interest (x)

22.548.65.6-18.433.6

Asset turnover, revenue / year-end assets (x)

0.710.800.810.800.85

Days sales outstanding (days)

56.258.852.244.744.0

Days inventory outstanding (days)

123.1129.0130.2142.4111.1

Days payables outstanding (days)

16.128.911.215.213.0

Cash conversion cycle (days)

163.2158.9171.2171.9142.1

Income Statement (FY2025–LTM Jun-2026)

MetricFY2025LTM Jun-2026

Revenue (KRW Mn)

50,11647,032

Gross profit (KRW Mn)

7,8348,086

Operating income (KRW Mn)

2,2302,275

Net income (KRW Mn)

2,3402,524

EBITDA (KRW Mn)

3,9343,963

Operating cash flow (KRW Mn)

7,1664,568

Free cash flow (KRW Mn)

5,9063,231

Revenue by Region and Revenue by Region (%)

MetricLTM Jun-2025LTM Sep-2025LTM Dec-2025LTM Mar-2026LTM Jun-2026

Export revenue (KRW Mn)

1,7802,2801,8101,370790

Total revenue (KRW Mn)

51,18050,49050,11048,27047,030

Export share (%)

3.54.53.62.81.7

Valuation Snapshot

MetricValueSource

Last close (15 Oct 2026)

KRW 931

S3

1-month return

-6.5%

S3

6-month return

-21.5%

S3

1-year return

-9.8%

S3

52-week range

KRW 837–1,323 (ETF쇼핑, to 15 Oct 2026). Investing.com shows KRW 814–1,527 (as of Aug 2026) over a different look-back window.

S3, S15

Beta (5-year)

0.31 (S&P) / 0.387 (StockHub)

S2, S16

Average daily volume

About 56,000 shares (20-day, Sep 2026). Investing.com shows a 3-month average of about 300,000, which reflects event spikes.

S2, S15

Share Price

MetricQ2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026

Quarter-end share price (KRW)

1,0231,0391,0471,148838

Valuation Multiples

MultipleBolakBasisSource

P/E (trailing)

22.1x

LTM EPS KRW 42.13

S2; computed

P/E (FY2025)

23.8x

FY2025 EPS KRW 39.06

S2, S3

EV/EBITDA (trailing)

12.5x

EV about KRW 49.4bn ÷ LTM EBITDA KRW 3.96bn

Computed from S2, S3

EV/Sales (trailing)

1.05x

EV ÷ LTM revenue KRW 47.03bn

Computed

P/B

1.12x

BVPS KRW 829.47 (Jun 2026)

S2; computed

P/FCF

About 17x

LTM FCF KRW 3.23bn

Computed from S2

Dividend yield

0.75%

FY2025 DPS KRW 7

Computed from S3

Altman Z-score / Piotroski F-score

6.39 / 6

S&P, Sep 2026

S2

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

DPS, split-adjusted (KRW)

14755457557

Payout ratio (%)

3427466118143501818

Capital Markets

ItemDetailSource

Authorisation

KRW 1.5bn treasury-share acquisition trust (board resolution, 6 Jul 2026)

S3

Implied size

About 1.5–1.6 million shares at KRW 931–1,000 (about 2.6% of shares outstanding; computed)

Computed

Execution

Daily trust purchases of about 10,000–20,000 shares observed Aug–Oct 2026; status report filed 6 Oct 2026

S4

Prior buybacks

None in FY2016–FY2025

S2, S3

Credit ratings (Moody's / S&P / Fitch)

Not rated; no public bonds

—

Debt maturity profile

FY2025: KRW 1,032M current portion of long-term debt (due within 2026); KRW 8.1M long-term debt; leases of KRW 64M

S2

Mar 2026

Current portion of long-term debt still KRW 1,032M; total debt KRW 1.08bn

S2

Interest expense

KRW 66M (FY2025); interest coverage about 34x

S2

Analyst Conclusions

Guidance and consensus

Management guidance: not publicly disclosed. Bolak issues no forward guidance.

Consensus: not available, as there is no sell-side coverage [S16].

Implied run-rate. H1 FY2026 revenue was about KRW 23.7bn [S3, S15]. Q2 FY2026 operating profit was KRW 0.7bn [S3], and LTM operating profit was KRW 2.28bn [S2]. On these figures, FY2026 revenue would land at about KRW 47–49bn with operating profit of about KRW 2–2.5bn, assuming H2 is similar to H2 FY2025. This is an analyst extrapolation, not a forecast from the company.

Bull case

  1. Margin normalisation is sustainable. Gross margin recovered from 9.0% (FY2024) to 17.2% LTM [S2]. If inventory discipline holds (DIO fell from 142 to 111 days [computed from S2]), operating margins of 5–6% are achievable. That would deliver operating profit of KRW 2.5–3.0bn on flat revenue.

  2. Balance-sheet optionality. Net cash of KRW 6.4bn (Jun 2026) [S2], land carried at KRW 19.1bn [S2], and a P/B of 1.12x mean the downside is cushioned by tangible assets. The first-ever KRW 1.5bn buyback [S3] signals a shift toward capital returns that could expand under Korea's "Value-up" pressure.

  3. API and paclitaxel optionality. A reported Liporaxel-linked delivery patent [S12] and a natural-paclitaxel API market growing at an estimated 7.7% CAGR [S14] provide upside not reflected in a company with only 20% API revenue [S4].

Bear case

  1. Value-destructive returns. ROIC of about 4.5% sits below S&P's WACC estimate of 5.9% [S2]. Bolak earned less than KRW 2.5bn per year on KRW 49bn of equity in four of the last five years [S2].

  2. Top-line erosion. LTM revenue fell 8.1% to KRW 47.0bn by June 2026 [S2], and exports collapsed to about KRW 0.8bn LTM [S5]. R&D cuts (−30% over 4 years [S2]) limit Bolak's ability to win new briefs.

  3. Governance and disclosure discount. The controlling family holds 33.5% (39.8% including the second holder) [S2, S3]. Disclosure is minimal and there is no coverage [S16]. The stock trades on LG-family and drug-approval headlines [S11, S12] rather than fundamentals, so a re-rating requires governance change that is not in evidence.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Q3 FY2026 results~6 Nov 2026 (estimated) [S2]Revenue trend versus Q3 FY2025; gross margin at or above 16%; export recovery
Buyback completion and cancellation decisionTrust period (end date not disclosed)Whether repurchased shares are cancelled or held
FY2026 dividend decision~Feb 2027DPS at or above KRW 7; payout rising above 20%
FY2026 business report~Mar 2027Segment revenue and profit disclosure; customer concentration; nature of FY2024 charges
Debt repaymentThrough 2026KRW 1.03bn current portion of long-term debt [S2]; would make the company effectively debt-free
Liporaxel / paclitaxel commercial linkageAny timeDisclosure of supply or royalty agreements
Controlling-shareholder activityOngoingFurther insider purchases (stake trended from 33.31% to 33.53%) [S3]
Input costsOngoingBotanicals, sugar and sweetener prices; won exchange rate

Analyst verdict

Bolak is a well-capitalised, low-return, domestically focused ingredient manufacturer whose equity story is driven more by its balance sheet and corporate-control context than by operating momentum.

The FY2025 recovery was genuine but partly mechanical. Revenue reached a 10-year high of KRW 50.1bn, operating profit turned positive at KRW 2.23bn, and a working-capital release produced record free cash flow of KRW 5.9bn [S2, S3]. The more recent data are less encouraging. LTM revenue had fallen to KRW 47.0bn by June 2026, exports were drying up, and R&D spending had declined for four consecutive years before a marginal LTM uptick [S2, S5].

At KRW 931, the shares trade at about 1.1x book, about 22x trailing earnings, and about 12.5x trailing EV/EBITDA [S2, S3; computed]. These multiples look neither cheap on earnings nor expensive on assets. The net cash position (about 11% of market cap) and land carried well below likely market value provide a floor. The thin, volatile margin structure (9–17% gross, −4% to +7% operating over five years) caps the ceiling [S2].

The incremental positives are capital-allocation signals: a 40% dividend increase, the first treasury-share trust in at least a decade, and steady insider accumulation [S3]. These suggest management is responding to Korea's shareholder-return agenda. The open question is whether the buyback shares are cancelled and whether payouts rise meaningfully from about 18%.

The investment case strengthens materially only if three things happen together: (i) gross margin holds at or above 16% through FY2026, (ii) API or export revenue re-accelerates, and (iii) management commits to cancelling repurchased shares and to a formal payout policy. Absent these, the stock is likely to remain a range-bound, event-driven micro-cap, with episodic spikes tied to LG-related or paclitaxel headlines that fundamentals do not support [S11, S12].


DATA GAPS (NOT PUBLICLY DISCLOSED IN ACCESSIBLE SOURCES)

  • KOSPI listing date; pre-2009 corporate milestones; former-name change date.

  • Auditor identity; board composition (outside directors, committees, chair); executive ages, education, and tenure start dates; individual compensation breakdown.

  • Segment revenue and profit for FY2023–FY2025; segment × geography; country-level revenue; named customers and concentration.

  • Verbatim strategy statements; medium-term targets; guidance.

  • R&D centre details; patent grant chronology.

  • ESG ratings, emissions data, diversity metrics.

  • 3-year and 5-year total share-price returns; peer valuation multiples.

  • Terms of any Liporaxel/paclitaxel commercial arrangement; nature of the FY2024 "other operating expense" (KRW 0.98bn) and of the 20 Jul 2026 correction filing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / education / ageSource

Chung Kie-ryun (정기련)

Chief Executive Officer (대표이사); largest shareholder

CEO since at least 2009 (identified as CEO in 2016 and 2018 reporting); start date not publicly disclosed

—

S2, S10, S11

Hwangbo Dae-ho (황보대호)

Director; Head of Administration Team

—

Not publicly disclosed; listed as a related party holding 0.17%

S2, S3

Kim Byung-cheol (김병철)

Director; Head of Production Team

——

S2

Statutory auditor and other board members

Not publicly disclosed by name in accessible sources

———

“—” = not publicly disclosed.

Workforce Metrics

ItemFY2025Source

Average pay per director/auditor (4 persons)

KRW 120M

S3 (from S1)

Ratio to average employee pay

2.0x (employee average KRW 59.75M)

S3

Individually disclosed pay (≥ KRW 500M)

None disclosed. Korean law requires individual disclosure only above KRW 500M, which implies no director exceeded that level.

S3

Major Shareholders

HolderRelationshipStake (%)As ofSource

Chung Kie-ryun

CEO, largest shareholder

26.16

FY2025 year-end

S1

Hong Young-soon (홍영순)

Related party

6.71

FY2025 year-end

S1

Ko Hye-ryun (고혜련)

Related party

0.35

FY2025 year-end

S1

Hwangbo Dae-ho

Related party / director

0.17

FY2025 year-end

S1

Chung Hyo-i (정효이)

Related party

0.10

FY2025 year-end

S1

Controlling group total

—33.49

FY2025 year-end

S1

Controlling group total (latest)

—33.53

11 Jun 2026 filing

S3

Choi Kyung-ae (최경애)

Other 5%+ holder

6.31

Filed 5 Jan 2026

S3

National Pension Service

Institution

0.20

End-2024 (down from 0.59% in 2021)

S3

Minority shareholders (12,850 holders)

Free float

57.79

FY2025 year-end

S1

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeRelative positioning vs. Bolak

Flavours (global)

Givaudan (Switzerland)

Global flavour and fragrance leader; FY2025 sales CHF 7,472M

Vastly larger; full-service creative flavour development; supplies multinational food and beverage companies in Korea [S19]

Flavours (global)

Symrise (Germany)

Global flavour, fragrance, and nutrition supplier; FY2025 sales EUR 4,929M

Vastly larger; strong in Asia [S20]

Flavours (global)

IFF (USA)

Global flavours, fragrances, and ingredients

—

Flavours (global)

dsm-firmenich (Switzerland/Netherlands)

Global flavour, fragrance, and nutrition

—

Flavours (Japan/Asia)

Takasago International; T. Hasegawa

Japanese flavour houses active in Korea

—

Natural colours

Oterra; GNT Group

Global natural-colour specialists

—

Gum base

Global gum-base specialists (e.g., Gum Base Co., Italy) and captive gum-base production at large confectioners

Specialist producers

Bolak competes as a domestic supplier with likely logistics and service advantages (inference)

Food additives (Korea)

Diversified Korean ingredient groups, e.g., Samyang Corp (sweeteners), Daesang, CJ CheilJedang (bio-ingredients)

Large domestic chaebol ingredient businesses

Much larger; overlap in sweeteners and functional additives only

Taxane APIs

Samyang Holdings biopharma (plant-cell-culture paclitaxel, "Genexol"); Chinese and Indian taxane API makers

Domestic and Asian API producers

Samyang is the domestic benchmark. It pioneered mass production of paclitaxel by plant-cell culture in 1995 and supplies API to about 30 countries [S13-related DailyPharm coverage]. Bolak uses a natural-extraction route.

Cellulose ethers (CMC)

Global CMC producers (e.g., Nouryon, Ashland, Daicel)

Large chemical producers

Bolak is a niche pharma- and food-grade supplier

Peer Comparison FY2025

MetricBolak (FY2025)Givaudan (FY2025)Symrise (FY2025)

Revenue

KRW 50.1bn

CHF 7,472M

EUR 4,929M

Organic / like-for-like growth

+5.3% (reported)

+5.1% LFL

+2.8% organic

Gross margin

15.6%43.5%—

EBITDA margin

7.9%

23.4% reported (24.2% comparable)

21.9% (adjusted)

Net margin

4.7%14.3%—

R&D intensity

1.6%——

Recent Developments

Bolak issues very few press releases, so the register relies mainly on regulatory filings and market events. Coverage by Korean financial media in the period is sparse.

*Older but still market-relevant: on 8 Oct 2024, shares rose about 21.8% intraday on the reported China NMPA approval of Liporaxel and Bolak's linked paclitaxel delivery-system patent [S12].

*Not identified in the period: guidance revisions, litigation, regulatory sanctions, layoffs, contract-win announcements, or product launches.

Company Snapshot

$35.3M

Revenue

141

Employees

1959

Founded

Hwaseong, South Korea

Headquarters

SWOT Analysis

Strengths

  • Fortress balance sheet. Net cash of KRW 6.84bn and total debt of KRW 1.10bn at FY2025, debt/equity of 0.023x, and a current ratio of 3.5x [S2].
  • Strong recent cash generation. FY2025 operating cash flow of KRW 7.17bn and free cash flow of KRW 5.91bn (11.8% FCF margin), with LTM FCF of KRW 3.23bn to Jun 2026 [S2].
  • Portfolio breadth. Six product families (flavours, colours, gum base, additives, APIs, fragrances and cosmetic ingredients) are documented [S2, S8], and no product family is known to dominate.
  • Pharmaceutical-grade franchise. APIs contributed 20% of Q2 FY2026 revenue [S4], including natural paclitaxel and docetaxel trihydrate [S2].
  • Hard-asset backing. Land is carried at historical cost of KRW 19.08bn [S2], equal to about 34% of market capitalisation at KRW 931. Book value per share of KRW 829 (Jun 2026) [S2] sits close to the share price, giving P/B of 1.12x.
  • Stable, experienced workforce. 141 employees with 14.6 years' average tenure [S1]. Payroll as a share of revenue fell from 18.4% (FY2021) to 16.8% (FY2025) [S3].
  • Low share-price beta. Beta of 0.31–0.39 [S2, S16], which suggests fundamentals are relatively insulated from market cycles. Event-driven spikes are the exception.

Weaknesses

  • Low and volatile margins. Operating margin ranged from −3.76% to 6.78% over FY2021–FY2025, and gross margin fell to 9.03% in FY2024 [S2].
  • Structurally weak returns. ROE of 4.8% (FY2025) and S&P-computed ROIC of 4.46% (TTM) [S2] sit below the S&P-estimated WACC of 5.92% [S2]. The business currently destroys economic value at the margin.
  • Heavy inventory. Days inventory outstanding was 111–142 over FY2021–FY2025, and the cash conversion cycle was 142–172 days [S2; computed]. This ties up capital and creates write-down risk.
  • Declining R&D investment. R&D fell 30% from KRW 1.14bn (FY2021) to KRW 0.80bn (FY2025) [S2].
  • Domestic dependence. Exports were only about 1.7–4.5% of LTM revenue over Jun 2025 – Jun 2026 [S5].
  • Poor disclosure and visibility. There are no IR materials, no English reporting, and no analyst coverage (zero reports per StockHub [S16]). Segment profit is not disclosed.
  • Revenue momentum has turned negative. LTM revenue to Jun 2026 was KRW 47.0bn, −8.1% versus FY2025 [S2].

Opportunities

  • Oncology API growth. The natural-paclitaxel API sub-segment is estimated to grow at a 7.7% CAGR [S14]. Bolak's reported Liporaxel-linked delivery patent could generate supply or royalty income if Liporaxel's Chinese commercialisation scales [S12].
  • Clean-label and natural colours. Bolak already produces natural extracted colours [S8]. Reformulation away from synthetic dyes in export markets favours natural colour suppliers.
  • Capital-return upside. At a KRW 7 dividend, FY2025 payout was only about 18% [S3]. Net cash of KRW 6.8bn [S2] leaves room for higher payouts or larger buybacks. A first KRW 1.5bn trust was contracted in Jul 2026 [S3].
  • Korea "Value-up" programme. KRX policy pressure on sub-book or low-P/B companies to raise shareholder returns (programme context; Bolak has not filed a value-up plan in accessible sources) could catalyse further buybacks or cancellations.
  • Asset monetisation. Land carried at historical cost of KRW 19.1bn [S2] may carry unrecognised revaluation upside. Market value is not disclosed.

Threats

  • Input-cost inflation. Raw materials were KRW 27.8bn in FY2025, about 66% of cost of sales [S5]. A repeat of the FY2023–FY2024 margin squeeze (gross margin 17.0% → 9.0%) would wipe out profits [S2].
  • Customer concentration and related-party scrutiny. The 2016 media allegation of LG-related sales favouritism [S10] shows reputational and regulatory sensitivity. Any loss of a major domestic customer would be material relative to KRW 47–50bn revenue.
  • Low-cost Asian competition. Chinese competition is intensifying even for leaders: Givaudan noted pressure in fragrance ingredients in 2025 [S19].
  • API regulatory risk. GMP inspection outcomes or dossier issues could interrupt API sales, which were 20% of Q2 FY2026 revenue [S4].
  • Theme-stock volatility. Price swings tied to LG-family news (+120% in 3 days in May 2018 [S11]) and to drug-approval headlines (+21.8% intraday in Oct 2024 [S12]) create disconnects from fundamentals.
  • Export decline. LTM export revenue fell from about KRW 2.3bn (Sep 2025) to about KRW 0.8bn (Jun 2026) [S5]. If structural, this would remove the main growth outlet.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
21 Mar 2025FY2024 business report filed: operating loss KRW 1.79bn, net loss KRW 1.51bn, 135 employees S2, S3Confirms the FY2024 trough
28 Apr 2025Q1 FY2025 preliminary results disclosed (fair disclosure) S3Start of FY2025 recovery reporting
29 Apr 2025FY2024 dividend of KRW 5 per share paid, held flat despite the net loss S3Dividend continuity
7 Aug 2025Q2 FY2025 preliminary results disclosed S3—
3 Nov 2025Q3 FY2025 preliminary results disclosed S3—
29 Dec 2025Ex-dividend date for FY2025 S2, S16—
31 Dec 2025FY2025 year-end: cash KRW 7.94bn, debt KRW 1.10bn, inventory KRW 12.9bn S2Strongest balance sheet in the 5-year window
5 Jan 2026Choi Kyung-ae files a 6.31% large-holding report S3New significant holder; float tightens
23 Feb 2026FY2025 cash dividend of KRW 7 per share (about KRW 0.42bn) approved S3+40% DPS; payout about 18%
18 Mar 2026FY2025 business report filed: revenue KRW 50.1bn (+5.3%), operating profit KRW 2.23bn, net income KRW 2.34bn, 141 employees S1, S3Turnaround confirmed; 10-year revenue high
–Annual general meeting for FY2025 —Agenda not publicly disclosed in accessible sources
31 Mar 2026Quarter-end share price KRW 1,148 (market cap about KRW 68.8bn) S552-week high zone
24 Apr 2026FY2025 dividend paid S3—
29 Apr 2026Q1 FY2026 preliminary results disclosed (revenue about KRW 11.2bn; EPS KRW 9.06) S3, S15Revenue lower YoY
9 Jun 2026Largest-shareholder ownership change report: group stake 33.51% S3Insider buying near lows
11 Jun 2026Further ownership change report: 33.53% S3Continued insider accumulation
Jun 2026Shares trade near the 52-week low (KRW 814–838 range; quarter-end KRW 838) S5, S15Down about 27% from the March level
6 Jul 2026Major-matters report: KRW 1.5bn treasury-share acquisition trust contract S3, S4First buyback in at least 10 years
8 Jul 2026Shares rise about 12.9% intraday to KRW 964 S16Market reaction to buyback and recovery expectations
9 Jul 2026Report on securities holdings of executives and major shareholders S4Insider dealing disclosure (detail not disclosed)
20 Jul 2026Amended Q3 FY2025 quarterly report filed (기재정정) S4Correction to prior filing; nature not disclosed
29 Jul 2026Q2 FY2026 preliminary results: revenue KRW 12.5bn, operating profit KRW 0.7bn, net income KRW 0.9bn S3Sequential revenue recovery (+11.5% vs Q1)
13 Aug 2026Half-year FY2026 report filed; Q2 mix: food additives 56%, other 24%, API 20% S4Latest segment visibility
Aug–Oct 2026Buyback execution through trust at about 10,000–20,000 shares per day S4Supportive of the share price
6 Oct 2026Trust-based treasury-share acquisition status report filed S4Interim buyback progress (amounts not disclosed in accessible sources)
15 Oct 2026Shares close at KRW 931 (−4.6% on the day); 1-year return −9.8%; 6-month return −21.5% S3Shares back near lows despite the buyback
~6 Nov 2026 (estimated)Q3 FY2026 results expected S2Next catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue rose from KRW 39,764 Mn in FY2021 to KRW 50,116 Mn in FY2025.
Bolak Company Limited — Income Statement: Revenue & Gross Profit
Series (KRW Mn)FY2021FY2022FY2023FY2024FY2025
Revenue39,76448,43546,77447,60050,116
Cost of revenue33,31540,20941,13543,30442,282
Gross profit6,4498,2255,6394,2967,834

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. S1DART FY2025 Business Report (사업보고서), rcpNo 20260318000334, data extracted via ETF쇼핑 company page — FY2025; filed 18 Mar 2026
  2. S2S&P Global Market Intelligence data via StockAnalysis.com (income statement, balance sheet, cash flow, statistics, profile) — FY2021–FY2025, TTM to Jun 2026; accessed Sep–Oct 2026
  3. S3ETF쇼핑 (etfshopping.com) stock, dividend, earnings, and company pages, built from DART filings — 10-year history; updated 12 Oct 2026
  4. S4Butler (butler.works) company dashboard, DART-based — Segment mix Q2 FY2026; disclosure list to 6 Oct 2026
  5. S5ValueLine / DataHero (valueline.co.kr) LTM income statement, DART-based — LTM Jun 2025 – Jun 2026
  6. S6Morningstar company profile — FY2025
  7. S7Simply Wall St company page — 2026
  8. S8EMIS company profile — Undated legacy profile
  9. S9PatSnap Discovery company page — Undated
  10. S10Bizhankook investigative article on ownership and LG-related sales — Dec 2016
  11. S11eToday, LG succession share-price surge — 21 May 2018
  12. S12Asia Economy (아시아경제), Liporaxel-related share-price surge — 8 Oct 2024
  13. S13DailyPharm, MFDS approval of Liporaxel oral paclitaxel — 9 Sep 2016
  14. S14Market Glass (formerly Global Industry Analysts) bulk paclitaxel report summary via GII Korea — Nov 2025
  15. S15Investing.com (Korean, Italian, and UK editions) — Apr–Aug 2026
  16. S16StockHub.kr — Jul–Oct 2026
  17. S17Bolta.io public business-registry extract (Hwaseong) — Oct 2026
  18. S18Cbonds company page — Undated
  19. S19Givaudan FY2025 full-year results release — Jan 2026
  20. S20Symrise FY2025 results (EQS release and trade press) — Mar 2026
  21. S21Logokit brand profile — Undated

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.